obi-3424
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 7, 2018 (NCT03592264)
Timeline
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Alkylating agent
AKR1C3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](OP(=O)(N1CC1)N2CC2)C3=CC(OC4=CC(=CC=C4)C(=O)N(C)C)=C(C=C3)[N+]([O-])=O- Mol. weight
- 460.4202 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- NCATSX6SH5T8H76 ↗
- ChEMBLCHEMBL4297474 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04315324 | Phase 2 | May 30, 2020 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT03592264 | Phase 1/Phase 2 (Phase 2) | Jun 7, 2018 | OBI Pharma, Inc, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| OBI Pharma, Inc | For profit | 1 | 1 | 1 | 2018 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1